Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:39 2024-04-26 am EDT			5-day change	1st Jan Change
17.3 ^SEK	+3.72%		+6.00%	+22.00%

Apr. 04	Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election	CI
Mar. 19	Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	CI

Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023

February 28, 2024 at 02:00 am EST

Vicore Pharma Holding AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was SEK 310.94 million compared to SEK 288.42 million a year ago. Basic loss per share from continuing operations was SEK 3.22 compared to SEK 3.99 a year ago.

Latest news about Vicore Pharma Holding AB

Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election	Apr. 04	CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis	Mar. 19	CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate	Feb. 09	MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study	Jan. 04	CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates	Jan. 02	CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer	Dec. 18	CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting	23-10-31	CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106	23-10-27	CI
Certain Shares of Vicore Pharma Holding AB are subject to a Lock-Up Agreement Ending on 11-SEP-2023.	23-09-10	CI
Vicore Pharma's New CEO to Formally Take Office	23-09-08	MT
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Vicore Pharma Holding AB Reports Data from EndoPAT® Exploratory Trial	23-08-22	CI
Vicore Pharma Names New CEO to Start in September	23-07-13	MT
Vicore Pharma Holding AB Announces Executive Changes	23-07-13	CI
Vicore Pharma Initiates Recruitment Process as CEO Plans Retirement	23-07-05	MT
EU Grants Patent to Vicore Pharma's Improved Pulmonary Fibrosis Drug Candidate	23-06-07	MT
Transcript : Vicore Pharma Holding AB - Special Call	23-05-26
Vicore Pharma Holding AB Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients	23-05-19	CI
Vicore Pharma Holding AB Strengthens Its Board of Directors	23-05-12	CI
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Vicore Pharma Holding AB Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction	23-05-03	CI
Vicore Pharma Holding AB Receives Innovation Passport Designation by the UK Regulatory Agency MHRA for C21 in IPF	23-03-29	CI

Chart Vicore Pharma Holding AB

Duration

Period

More charts

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.3 SEK

Average target price

61.5 SEK

Spread / Average Target

+255.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VICORE PHARMA HOLDING AB	+22.00%	176M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs